
Overview
Biotechnology firm's Q4 revenue rose 3%, beating analyst expectations
Adjusted EPS for Q4 beat analyst expectations
Company announced FDA approvals for EYLEA HD and Libtayo
Outlook
Regeneron expects 2026 GAAP R&D expenses between $6.45 bln and $6.68 bln
Company anticipates FDA decision on EYLEA HD pre-filled syringe in Q2 2026
Regeneron projects 2026 GAAP gross margin on net product sales at 79%-80%
Result Drivers
DUPIXENT SALES - Dupixent global net sales increased 34% in Q4 2025, helped by new approvals in Japan and Europe
EYLEA HD DEMAND - EYLEA HD U.S. net sales rose 66% in Q4 2025 due to increased demand, despite competitive pressures
SANOFI COLLABORATION - Collaboration revenue from Sanofi increased due to higher share of profits from commercialization of antibodies
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $3.88 bln | $3.80 bln (19 Analysts) |
Q4 Adjusted EPS | Beat | $11.44 | $10.62 (19 Analysts) |
Q4 EPS |
| $7.86 |
|
Press Release: ID:nGNXbFdfdZ
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.